Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Construction of Vascular Tissues with Macro-Porous Nano-Fibrous Scaffolds and Smooth Muscle Cells Enriched from Differentiated Embryonic Stem Cells

  • Jiang Hu ,

    Contributed equally to this work with: Jiang Hu, Changqing Xie

    Affiliation Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor, Michigan, United States of America

  • Changqing Xie ,

    Contributed equally to this work with: Jiang Hu, Changqing Xie

    Affiliation Department of Internal Medicine, Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States of America

  • Haiyun Ma,

    Affiliation Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor, Michigan, United States of America

  • Bo Yang,

    Affiliation Department of Cardiac Surgery, Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States of America

  • Peter X. Ma , (PXM); (YEC)

    Affiliations Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor, Michigan, United States of America, Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America, Macromolecular Science and Engineering Center, University of Michigan, Ann Arbor, Michigan, United States of America, Department of Materials Science and Engineering, University of Michigan, Ann Arbor, Michigan, United States of America

  • Y. Eugene Chen (PXM); (YEC)

    Affiliation Department of Internal Medicine, Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States of America

Construction of Vascular Tissues with Macro-Porous Nano-Fibrous Scaffolds and Smooth Muscle Cells Enriched from Differentiated Embryonic Stem Cells

  • Jiang Hu, 
  • Changqing Xie, 
  • Haiyun Ma, 
  • Bo Yang, 
  • Peter X. Ma, 
  • Y. Eugene Chen


Vascular smooth muscle cells (SMCs) have been broadly used for constructing tissue-engineered blood vessels. However, the availability of mature SMCs from donors or patients is very limited. Derivation of SMCs by differentiating embryonic stem cells (ESCs) has been reported, but not widely utilized in vascular tissue engineering due to low induction efficiency and, hence, low SMC purity. To address these problems, SMCs were enriched from retinoic acid induced mouse ESCs with LacZ genetic labeling under the control of SM22α promoter as the positive sorting marker in the present study. The sorted SMCs were characterized and then cultured on three-dimensional macro-porous nano-fibrous scaffolds in vitro or implanted subcutaneously into nude mice after being seeded on the scaffolds. Our data showed that the LacZ staining, which reflected the corresponding SMC marker SM22α expression level, was efficient as a positive selection marker to dramatically enrich SMCs and eliminate other cell types. After the sorted cells were seeded into the three-dimensional nano-fibrous scaffolds, continuous retinoic acid treatment further enhanced the SMC marker gene expression level while inhibited pluripotent maker gene expression level during the in vitro culture. Meanwhile, after being implanted subcutaneously into nude mice, the implanted cells maintained the positive LacZ staining within the constructs and no teratoma formation was observed. In conclusion, our results demonstrated the potential of SMCs derived from ESCs as a promising cell source for therapeutic vascular tissue engineering and disease model applications.


Vascular smooth muscle cells (SMCs) constitute the principal layer of all small and large blood vessels in the body. Functional deficiency of vascular SMCs plays a central role in the progression of a large number of major human diseases [1], [2]. Many therapeutic treatments to cardiovascular diseases have either enhanced in situ blood vessel formation or implanted in vitro constructed blood vessels. The efforts to construct tissue-engineered blood vessels in vitro using mature vascular SMCs isolated from donor vascular tissues have been extensively reported [3][5]. However, mature vascular SMCs have limited ability to proliferate and the cell source is very limited. Embryonic stem cells (ESCs) have shown promise as a therapeutic cell source because of the capacity of self-renewal and the potential to differentiate into various cell types in the adult body. A growing number of studies have demonstrated the differentiation capabilities of ESCs into lineage-specific cells under the appropriate stimuli and the control of a range of signal pathway complex [6]. We and others have utilized a two-dimensional monolayer culture system for cardiovascular differentiation [7][9], which has facilitated the dissection of molecular and cellular mechanisms of cardiovascular development [10], [11]. However, one of the major challenges for the application of ESC-derived SMCs to the construction of functional vascular tissues is the heterogeneous cell population derived from pluripotent stem cells, which may lead to teratoma formation or inferior tissue organization. Thus strategies have to be developed to efficiently induce and enrich SMCs before the cells can be used for vascular tissue engineering. Another challenge is to develop a suitable porous scaffold to support vascular tissue development. We recently developed three-dimensional (3D) macro-porous nano-fibrous (NF) scaffolds and found them to preferentially support contractile phenotype of human aorta SMCs under in vitro culture conditions [3], which may therefore serve as a suitable scaffold for constructing vascular tissues. In this study, SMCs derived from the differentiated mouse SM22α−/−LacZ ESCs were enriched by positive cell sorting, and the 3D NF scaffolds were shown to support the growth of sorted cells both in vitro and in vivo.

Materials and Methods

SMC differentiation of SM22α−/−LacZ ESCs

SM22α−/−LacZ ESCs were kindly provided by Dr. Li Li from Wayne State University, who published the SM22α-KO mice data previously [12]. The ESCs were expanded and induced to differentiate into SMCs in vitro when treated with 10−5 M all trans-retinoid acid (RA) following the protocol described in our previous publication [8]. The vehicle dimethyl sulfoxide (DMSO) treatment served as a spontaneous differentiation control.

β-gal staining

A β-gal staining kit (Invitrogen, Carlsbad, CA) was used for β-gal staining. The derived cells after treatment with either the DMSO or RA for different time periods were fixed with 2% formaldehyde and incubated with an X-gal containing solution, according to the manufacturer's instructions. For β-gal staining of the implants, sections (5 µm thick) were generated using a cryostat (CM 1850, Leica Microsystems) and thaw-mounted onto glass slides and stored at −20°C until staining. The cell nuclei were counterstained with fast red (Vector Lab, Burlingame, CA). Implant samples were also stained with hematoxylin and eosin (H&E).

Fluorescence activated cell sorting (FACS)

Cell suspension preparation and FACS were performed following published methods [13]. Briefly, differentiated cells cultured on Petri dishes were digested with trypsin and then centrifuged to remove the supernatant. Cells were re-suspended in staining medium to a density of ∼107 cells/mL and loaded with 5-chloromethylfluorescein di-β-D-galactopyranoside (FDG) by adding 100 µL 2 mM pre-warmed FDG working solution. Cells were mixed rapidly and incubated in a 37°C water bath for 1 minute. Then the FDG loading was stopped by adding 1.8 mL ice-cold staining buffer. The cells were kept on ice prior to FACS. The background autofluorescence compensation was set with unstained cells. The cells with fluorescence labeling (LacZ positive) were analyzed and sorted using the FACSCalibur™ system (BD Biosciences, San Jose, CA) following the user's guide.

Immunofluorescence staining

Sorted cells were replated on 0.1% gelatin-coated chamber vessels (BD Biosciences) and incubated in the culture medium overnight. Cells were then fixed, permeabilized and incubated overnight with smooth muscle-α-actin (α-SMA) antibody at 1∶1000 dilutions (Millipore, Temecula, CA). After rinsing, samples were incubated with Alexa Fluor-488 conjugated secondary antibody (Molecular Probe, Eugene, OR) for 1 hour. The cell nuclei were co-stained with 4′,6-diamidino-2-phenylindole (DAPI) (Molecular Probe). Samples were observed under an Olympus BX51 microscope.

Fabrication of 3D macro-porous NF scaffolds

3D macro-porous NF scaffolds were fabricated following our previous publication [3]. Briefly, 10wt/v% poly(l-lactide) (PLLA) (Boehringer Ingelheim, Ingelheim, Germany) in tetrahydrofuran solution was cast into an assembled sugar template from bound sugar spheres with a diameter of 125–250 µm under a mild vacuum. After phase separation at −20°C overnight, the polymer-sugar composite was immersed into cyclohexane to exchange tetrahydrofuran for 2 days. The resulting polymer-sugar composites were freeze-dried and the sugar spheres were leached out in distilled water. The obtained macro-porous NF scaffolds were freeze-dried again and cut into circular disks with dimensions of 3.6 mm in diameter and 1 mm in thickness. The scaffolds were sterilized with ethylene oxide before use.

Cell culture on 3D macro-porous NF scaffolds

The sterile 3D NF scaffolds were pre-wetted in 70% ethanol for 30 minutes, washed three times with PBS for 30 minutes each, and twice in cell culture medium for 2 hours each. 2.5×105 cells were seeded on each scaffold. The cell-seeded scaffolds were then transferred to 6-well plates on an orbital shaker [14]. The medium was changed twice a week.

Scanning electron microscopy (SEM) observation

Samples were rinsed in PBS, fixed in 2.5% glutaraldehyde and 2% paraformaldehyde overnight, and post-fixed in 1% osmium tetroxide for 1 hour. Samples were dehydrated in increasing concentrations of ethanol and hexamethyldisilizane. The samples were then sputter-coated with gold and observed under a scanning electron microscope (Philips XL30 FEG).

Gene expression analysis with quantitative real-time PCR

Total cellular RNA and cDNA were prepared with an RNeasy mini kit (Qiagen, Valencia, CA) and superscript III first-strand synthesis method (Invitrogen, Carlsbad, CA) following the manufacturer's instructions respectively. PCR amplification was performed with primers selective for individual genes with SYBR Green supermix kit (Bio-rad, Hercules, CA). PCR primers and reaction conditions were described previously [11] and in Table S1. All gene expression level of individual RNA sample was normalized against 18S RNA as an internal standard.

Histological observation

The cell-scaffold constructs were washed in PBS, fixed with 3.7% formaldehyde, dehydrated in ethanol, and embedded in paraffin. Sections (5 µm thick) were stained with H&E method. For immunofluorescence analysis of SMC specific markers, the slides were de-paraffinized, blocked with serum, incubated with primary antibodies to α-SMA (1∶50 dilution, Millipore) and then incubated with Alexa Fluor-592 conjugated secondary antibodies (Invitrogen, Carlsbad, CA). Samples were observed under an Olympus BX51 microscope.

Subcutaneous implantation

After the sorted SMCs were seeded and cultured on scaffolds for 24 hours, the cell-scaffold constructs were implanted into subcutaneous pockets on nude mice. Briefly, 6–8 weeks old male nude mice (Charles River Laboratories, Wilmington, MA) were anesthetized with isofluorane. Two dorsal midsagittal incisions were made on the disinfected back. One subcutaneous pocket was created on each side of each incision using blunt dissection and one scaffold was implanted into each pocket. Four samples were implanted randomly for each group (n = 4). The mice were euthanized and the implants were harvested at 2 weeks for β-gal staining. The animal procedures followed the approved protocol by the University of Michigan Committee on Use and Care of Laboratory Animals.

Statistical analysis

Numerical data were reported as mean ± S.D. from triplicate cell culture (n = 3). The Student's t-test was applied to test the significance between the groups. The value of p<0.05 was considered statistically significant.


Enrichment of SMCs from differentiated SM22α−/−LacZ ESCs

Under the treatment of RA, the SM22α−/−LacZ ESCs monolayer underwent dramatic morphological changes. Throughout this process, the cells kept proliferating and gradually grew to confluence. In the meantime, the cells acquired an SMC-like shape starting from day 2 (Fig. 1A). Gradually, the SMC-like cells dominated the culture from day 5 and became confluent with a significant morphological difference compared with the DMSO treated spontaneous differentiation culture, which showed more random cellular shapes. The β-gal staining result indicated that RA treatment induced SM22α−/−LacZ ESCs to differentiate into SMCs in a time-dependent manner (Fig. 1B). The number of β-gal positive cells increased with inducing time. In contrast, only sporadic staining was observed in spontaneously differentiated culture. Moreover, β-gal activity was dramatically enhanced in RA-treated SM22α−/−LacZ ESCs compared to DMSO-treated cells at day 8 (data not shown). The differentiated cells were then sorted. After 6 days of RA induction, the derived SMC population from SM22α−/−LacZ ESCs were sorted by FACS with hypotonic introduction of 5-chloromethylfluorescein di-β-D-galactopyranoside (FDG), which is designed to react with intracellular glutathione and subsequent hydrolysis by β-galactosidase and generate fluorescent adduct [13]. To eliminate the possibility of contamination of non-specific cell types with low-level transient SM22α gene expression, the sorting gate threshold was set to a value higher than 102 fluorescence intensity. As a result, the sorted cells for further studies accounted for 20–25% of total LacZ positive cell population (Fig. 1C). Sorted cells displayed typical SMC-like morphology with a strong fluorescence signal (Fig. 1D) and strong expression of α-SMA evidenced by immunofluorescence staining (Fig. 1E). Gene expression analyses confirmed that much higher levels of the SMC specific genes, including α-SMA and SMMHC, were expressed in the purified cell population after FACS and simultaneously the expression level of both pluripotent marker (Oct4) and other cell lineage markers, such as endoderm marker AFP, mesoderm marker GATA2 and ectoderm marker NeuroD, was dramatically reduced (Fig. 1F). Collectively these results demonstrated that the above described method can be used for the enrichment of SMCs from the mixture of differentiated ESCs and thus allow us to generate purified SMCs in large quantities for further vascular tissue engineering applications.

Figure 1. Sorting of SMCs from RA-induced SM22α−/−

LacZ ESCs. (A) Morphology change of SM22α−/−LacZ ESCs under the treatment of DMSO (upper panel) or 10−5 M RA (lower panel) respectively as indicated time. (B) Comparison of β-gal staining of cells treated with either DMSO (left panel) or 10−5 M RA (right panel). The upper panel showed that β-gal staining positive cells accumulated with RA treatment time, while only sporadic β-gal staining positive cells existed in DMSO-treated cell population. The lower panel showed representative magnified images by day 8. Scale bar = 100 µm. (C–D) Using 5-chloromethylfluorescein di-β-D-galactopyranoside (FDG) to react with intracellular glutathione. In LacZ-positive cells derived from RA-induced SM22α−/−LacZ ESCs, the FDG–glutathione adduct was converted to a bright green fluorescent product and LacZ-positive cells were subsequently sorted through a GFP channel (C) and cultured (D). Left panel: bright field; middle panel: GFP channel; right panel: merge. Scale bar = 100 µm. (E) Immunofluorescence staining of SMCs derived from sorted LacZ-positive cells with SMC-specific marker α-SMA antibody. The nuclei were co-stained with DAPI. Scale bar = 100 µm. (F) Gene expression of sorted cells analyzed by quantitative real-time PCR, compared to undifferentiated ESCs (control, Ctrl) or cells before sorting. Before: before sorting; After: after sorting. *p<0.05.

In vitro culture of sorted SMCs on 3D NF scaffolds

Sorted SMCs were then seeded on 3D NF scaffolds (Fig. 2A&B) and cultured for 2 weeks in the medium containing DMSO or 10−5 M RA. After seeding for 24 hours, the cells aggregated inside the pores of the scaffolds (Fig. 2C&D). Gene expression analysis showed enhanced SMC marker gene expressions, including myocardin (MyoCD), α-SMA and SMMHC, for cells cultured on 3D NF scaffolds under continuous RA treatment, compared to DMSO treatment, while the expression of pluoripotent marker Nanog was kept inhibited by RA treatment (Fig. 3A). H–E staining showed that the cells distributed throughout the scaffold after 2 weeks of culture for both groups (Fig. 3B). However, immunofluorescence staining showed strong α-SMA positive staining in the constructs with continuous RA treatment. In contrast, weaker α-SMA staining was observed in the constructs treated with DMSO (Fig. 3C).

Figure 2. Representative SEM micrographs of NF scaffold and sorted SMCs seeded on the scaffold.

(A–B) Low and high magnification images of the NF scaffold respectively. The cells were seeded and cultured for 24 hours and observed at low (C) or high (D) magnifications. Arrows indicate the cell aggregates inside the pores of scaffolds.

Figure 3. In vitro culture of sorted SMCs on 3D NF scaffolds.

(A) Gene expression profiles of sorted SMCs before (Ctrl) and after seeded on NF scaffolds and cultured under the treatment of RA or DMSO for 2 weeks, respectively. (B) Histology of constructs cultured for 2 weeks with H–E staining. Left panel: DMSO treatment; right panel: RA treatment. (C) Immunofluorescence staining of α-SMA for constructs cultured for 2 weeks. Upper panel: DMSO treatment; Lower panel: RA treatment. Red: positive α-SMA expression; Blue: nuclei. Scale bar = 50 µm. *p<0.05.

Subcutaneous implantation of cell-scaffold constructs

After the sorted SMCs were seeded on the scaffold for 24 hours, the cell-scaffold constructs were subcutaneously implanted into nude mice. After 2 weeks of implantation, the tissue infiltration into the scaffolds was observed on all samples. Positive LacZ staining of implanted cells was observed, while no detectable LacZ staining was observed in the blank scaffold implants (Fig. 4A), which indicated the survival of implanted SMCs inside the scaffold under in vivo conditions and retained the marker gene expression. Meanwhile, the teroatoma development was not observed on the cell-scaffold construct implants (Fig. 4B).

Figure 4. Histology of constructs implanted subcutaneously for 2 weeks.

(A) β-gal staining. (Left) blank scaffold implants; (Right) cell-scaffold construct implants. Blue: positive LacZ staining; Red: nuclei. (B) H&E staining of cell-scaffold construct implants. Scale bar = 200 µm.


In this study, we presented a strategy to enrich SMCs from the differentiated ESCs and use the purified cells to construct vascular tissues on a macro-porous NF scaffold, which can serve as a potential platform for engineering therapeutic vascular tissues and for establishing vascular disease models. Although a number of in vitro SMC differentiation systems have been established, in which stem cells were induced to differentiate under the treatment of cytokines, growth factors or ECM components [8], [9], [15][19], there are limited publications showing the application of ESC-derived SMCs in vascular tissue engineering, largely owing to the heterogeneous properties of the cells. Given that ESCs have been considered to be a promising cell source for regenerating various tissues, we explored the capability of ESC-derived SMCs for constructing vascular tissues. SM22α is a 22 kDa protein that physically associates with cytoskeletal apparatus in contractile SMCs. SM22α-deficient (SM22α−/−LacZ) mice has been generated by gene targeting and used to study blood vessel development and gene function during embryogenesis, wherein, certain initiation codon of SM22α were replaced by the LacZ reporter [20], [21]. Previous study has shown that this replacement does not alter basal homeostatic function mediated by vascular SMCs in the developing mice and SM22α−/− mice are viable and fertile [20]. Here, we used the ESCs, which have been employed for the generation of SM22α−/−LacZ mice, to generate SMCs in vitro with LacZ staining as the positive selection marker. Naturally, the SM22α promoter is highly active in the heart tube and selectively expressed in a subset of arterial SMCs [20], [22][25]. Therefore, there was a possibility that cardiomyocytes might also be isolated using the SM22α promoter as the selecting marker. Our previous study has shown the SMCs, derived from ESCs or induced pluoripotent stem cells (iPSCs) by high dose (10−5 M) RA induction, had very low level of cardiomyocyte specific marker expression [8], therefore excluding the contamination of cardiomyocytes in our induction-sorting protocol. The results demonstrated that SM22α expression and the corresponding LacZ positive staining within the cell population sorted from differentiated ESCs exhibited a high degree of SMC specificity, as evidenced by the high level expression of SMC specific markers and diminished expression of other cell lineage markers.

A concern associated with the use of ESCs for therapies is the retention of undifferentiated pluripotent cells. Studies indicated that undifferentiated ESCs remained in embryoid bodies even after 28 days of differentiation and could be eradicated only by prolonged negative selection [18]. Undifferentiated ESCs are highly proliferative and have the potential to differentiate into unwanted cell lineages including teratoma formation, raising a significant concern over their use for therapeutic applications. The risk can be reduced if the ESCs are differentiated prior to transplantation [18], [26]. Here, we showed the absence of teratoma formation in our studies, likely benefited from the high efficiency of RA induced differentiation protocol and the positive sorting strategy. However, we observed that after being seeded and cultured on 3D NF scaffolds, the sorted cells could re-express the pluripotent genes (i.e., Nanog) when RA was withdrawn early from the culture medium, indicating that the sorted cells were not terminally differentiated and longer RA treatment may be necessary to drive the cells to a mature differentiated phenotype. Growth factors have also been shown to greatly affect the cell differentiation [27], [28]. The incorporation of a controlled-release capacity for RA or/and growth factors into the porous NF scaffolds [29] may further enhance functional vascular tissue regeneration.

Supporting Information

Table S1.

Primers Used for RT-PCR.



Author Contributions

Conceived and designed the experiments: JH CX YEC PXM. Performed the experiments: JH CX HM. Analyzed the data: JH CX BY. Wrote the paper: JH CX YEC PXM.


  1. 1. Schwartz SM, deBlois D, O'Brien ER (1995) The intima. Soil for atherosclerosis and restenosis. Circ Res 77: 445–465.
  2. 2. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767–801.
  3. 3. Hu J, Sun X, Ma H, Xie C, Chen YE, et al. (2010) Porous nanofibrous PLLA scaffolds for vascular tissue engineering. Biomaterials 31: 7971–7977.
  4. 4. Xu ZC, Zhang WJ, Li H, Cui L, Cen L, et al. (2008) Engineering of an elastic large muscular vessel wall with pulsatile stimulation in bioreactor. Biomaterials 29: 1464–1472.
  5. 5. Niklason LE, Abbott W, Gao J, Klagges B, Hirschi KK, et al. (2001) Morphologic and mechanical characteristics of engineered bovine arteries. J Vasc Surg 33: 628–638.
  6. 6. Pera MF, Tam PP (2010) Extrinsic regulation of pluripotent stem cells. Nature 465: 713–720.
  7. 7. Huang H, Zhao X, Chen L, Xu C, Yao X, et al. (2006) Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun 351: 321–327.
  8. 8. Xie CQ, Huang H, Wei S, Song LS, Zhang J, et al. (2009) A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells. Stem Cells Dev 18: 741–748.
  9. 9. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, et al. (2000) Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408: 92–96.
  10. 10. Huang H, Xie C, Sun X, Ritchie RP, Zhang J, et al. (2010) miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. J Biol Chem 285: 9383–9389.
  11. 11. Xie C, Huang H, Sun X, Guo Y, Hamblin M, et al. (2011) MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4. Stem Cells Dev 20: 205–210.
  12. 12. Shen J, Yang M, Ju D, Jiang H, Zheng JP, et al. (2010) Disruption of SM22 promotes inflammation after artery injury via nuclear factor kappaB activation. Circ Res 106: 1351–1362.
  13. 13. Poot M, Arttamangkul S (1997) Verapamil inhibition of enzymatic product efflux leads to improved detection of beta-galactosidase activity in lacZ-transfected cells. Cytometry 28: 36–41.
  14. 14. Xie C, Hu J, Ma H, Zhang J, Chang LJ, et al. (2011) Three-dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds. Biomaterials 32: 4369–4375.
  15. 15. Chen S, Lechleider RJ (2004) Transforming growth factor-beta-induced differentiation of smooth muscle from a neural crest stem cell line. Circ Res 94: 1195–1202.
  16. 16. Hirschi KK, Rohovsky SA, D'Amore PA (1998) PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141: 805–814.
  17. 17. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK (2004) Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 287: C1560–1568.
  18. 18. Sinha S, Wamhoff BR, Hoofnagle MH, Thomas J, Neppl RL, et al. (2006) Assessment of contractility of purified smooth muscle cells derived from embryonic stem cells. Stem Cells 24: 1678–1688.
  19. 19. Oishi K, Ogawa Y, Gamoh S, Uchida MK (2002) Contractile responses of smooth muscle cells differentiated from rat neural stem cells. J Physiol 540: 139–152.
  20. 20. Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, et al. (2001) Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol 21: 1336–1344.
  21. 21. Yang M, Jiang H, Li L (2010) Sm22alpha transcription occurs at the early onset of the cardiovascular system and the intron 1 is dispensable for its transcription in smooth muscle cells during mouse development. Int J Physiol Pathophysiol Pharmacol 2: 12–19.
  22. 22. Li L, Miano JM, Mercer B, Olson EN (1996) Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol 132: 849–859.
  23. 23. Kim S, Ip HS, Lu MM, Clendenin C, Parmacek MS (1997) A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol Cell Biol 17: 2266–2278.
  24. 24. Li L, Miano JM, Cserjesi P, Olson EN (1996) SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res 78: 188–195.
  25. 25. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, et al. (1996) The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122: 2415–2425.
  26. 26. Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, et al. (2003) Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 21: 1200–1207.
  27. 27. Srivastava S, Terjung RL, Yang HT (2003) Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 285: H1190–1197.
  28. 28. Hishikawa K, Nakaki T, Fujii T (1999) Transforming growth factor-beta(1) induces apoptosis via connective tissue growth factor in human aortic smooth muscle cells. Eur J Pharmacol 385: 287–290.
  29. 29. Wei G, Jin Q, Giannobile WV, Ma PX (2006) Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 112: 103–110.